Card Acquiring for Subscription and Rebill Nutra
negative option, autoship, continuity

Continuity nutra is classified as negative-option billing under Visa and Mastercard rules, and generalist acquirers usually exclude it in their underwriting policy. Even when they board the file, the first month of true rebill dispute volume typically triggers VAMP exposure and termination.

10-15% rolling over 180 days is the standard opening position for a new continuity file. Established merchants with documented dispute history below scheme thresholds and a clean claims profile can negotiate down to 5-10% over 90-180 days, particularly where chargeback-mitigation tooling is in place.

VAMP (live since April 2025) combines fraud and non-fraud disputes into a single ratio. Subscription nutra typically generates 'subscription cancelled' and 'cardholder does not recognise' disputes that count toward this ratio, so merchants need pre-debit notifications, clear billing descriptors and Ethoca/RDR enrolment to stay inside the Standard tier.

MCC 5122 (drugs, drug proprietors, druggists' sundries) or 5499 (misc food stores) are the defensible codes for nutraceuticals. Anything else — particularly 5814 or generic e-commerce codes — is a reclassification risk and a common trigger for mid-life MID termination.

Yes, but only with strict disclosure: trial terms, full rebill price and cancellation method must appear on the checkout page above the buy button, and Visa requires a pre-debit notification before the first rebill. Acquirers with continuity programmes will audit the checkout before boarding and during the relationship.

Yes, in most cases. Splitting one-time and recurring volume across MIDs keeps dispute ratios cleaner, isolates VAMP exposure to the rebill book, and lets the acquirer price each MID against its own risk profile. It also gives you redundancy if one MID is paused.